Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q1 2025 · 10-Q
Revenue$2.74M$2.74M−89.2% vs Q1 2024 Net Income$4.64M$4.64MN/M vs Q1 2024 EPS Diluted$1.15$1.15N/M vs Q1 2024 Operating Income-$14,920,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
Free Cash Flowderived$2,703,000N/M Margins · derivedOperating margin-544.7%−350.8 pt vs Q1 2024
Net margin169.4%+299.2 pt vs Q1 2024
ended Mar 31, 2025 · filed May 12, 2025 · 42 d after period end